Uncategorized

Snap Event: Snap Inc Highlights Latest Spectacles Device

https://snappartnersummit.com/?utm_medium=cpc&utm_source=google&utm_campaign=3Q_Google_Search_Beta_Brand_US_SPS2021&utm_term=%2Bsnap%20%2Bevent&utm_device=c&gclid=Cj0KCQjwkZiFBhD9ARIsAGxFX8Any3eKy4lAN

byBenzinga Newsdesk

May 20, 2021

1 minute read

Unusual Options Activity Insight: Carnival

By Benzinga Insights

Today, 5:04 PM

Unusual Options Activity Insight: Carnival Carnival (NYSE:CCL) shares experienced unusual options activity on Thursday. The stock price moved down to $24.07 following the option alert.

CCL

Takeda’s Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years

By Vandana Singh

Today, 5:04 PM

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022.

TAK

Varonis Systems Q3 EPS $0.05 Beats $0.02 Estimate, Sales $100.35M Beat $97.41M Estimate

By Benzinga Newsdesk

Today, 5:04 PM

Varonis Systems (NASDAQ:VRNS) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.02 by 150 percent. This is a 16.67 percent decrease over earnings of $0.06 per share from the

VRNS

Celestica Q4 EPS $0.44 Beats $0.32 Estimate, Sales $1.50B Beat $1.49B Estimate

By Benzinga Newsdesk

Today, 5:04 PM

Celestica (NYSE:CLS) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.32 by 37.5 percent. This is a 69.23 percent increase over earnings of $0.26 per share from the same

CLS

Snap Event: Snap Inc Highlights Latest Spectacles Device

Related Posts

Unusual Options Activity Insight: Carnival

Takeda’s Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years

Varonis Systems Q3 EPS $0.05 Beats $0.02 Estimate, Sales $100.35M Beat $97.41M Estimate

Celestica Q4 EPS $0.44 Beats $0.32 Estimate, Sales $1.50B Beat $1.49B Estimate